论文部分内容阅读
目的分析131I治疗重度甲状腺肿大伴甲亢的安全性以及治疗效果。方法对80例重度甲状腺肿大伴甲亢患者进行研究,依据治疗方法的不同分成2组,每组40例,观察组采用131I治疗,对照组患者采用抗甲状腺药物(ATD)治疗。对比2组体征改善、甲状腺质量减轻、及甲状腺功能检验指标变化等。结果通过系统治疗,2组患者的手抖以及多汗症等体征均有改善,观察组治愈率为87.50%(35/40),对照组治愈率为62.50%(25/40),2组间差异显著(P<0.05)。与对照组相比观察组甲状腺质量及甲状腺激素变化情况均得到显著改善(P<0.01)。结论131I治疗重度甲状腺肿大伴甲亢安全有效,值得临床推广应用。
Objective To analyze the safety and therapeutic effect of 131I in patients with severe goiter and hyperthyroidism. Methods Eighty patients with severe hyperthyroidism and hyperthyroidism were studied. According to the different treatment methods, they were divided into two groups of 40 cases each. The observation group was treated with 131I and the control group with anti-thyroid drug (ATD). Compared with the two groups, signs of improvement, thyroid mass reduction, and thyroid function test indicators change. Results The results showed that the symptoms such as hand shaking and hyperhidrosis were improved in the two groups. The cure rate was 87.50% (35/40) in the observation group and 62.50% (25/40) in the control group The difference was significant (P <0.05). Compared with the control group thyroid gland quality and thyroid hormone changes were significantly improved (P <0.01). Conclusion 131I treatment of severe goiter with hyperthyroidism is safe and effective, worthy of clinical application.